Funding
← Back to your selection

Mubadala Capital

Activity from announced rounds

Activity in this selectionUnited States · Jan 31, 2026 · Jan 1, 2026

Mubadala Capital is the investment manager whose official portfolio includes Ollin, Alloy, Juvena and Crusoe.

Recorded funding activity

Ollin develops retinal-disease antibodies. Alloy supplies discovery platforms and services, while Crusoe develops computing infrastructure. The manager remains separate from Mubadala Investment Company; the Precision Neuroscience relation stays in draft.

Sources
Rounds participated in
1
Confirmed lead rounds
—
1 roles undisclosed
New companies
1
First participation on record · 0 follow-on
Funding in participating rounds
$33.5M
1 disclosed · full round size, not this investor’s share

By stage

Series B1

By primary sector

Biotech1

By country

United States1

Rounds

1 in this selection